

**Follow-Up to 714-X Review**  
**August 12, 2004**

The National Cancer Institute's Office of Cancer Complementary and Alternative Medicine seeks to identify and facilitate further research of alternative medical approaches to cancer treatment with promising preliminary information. One of the programs through which such approaches are identified is the NCI's Best Case Series (BCS) Program which reviews the documentation on groups of cancer patients who have previously received alternative interventions and assesses if the information obtained is sufficient to justify NCI-initiated prospective research.

714-X is a compound manufactured and distributed by C.E.R.B.E. Distribution, Incorporated located in Quebec, Canada. 714-X is not approved by the Food and Drug Administration for use as a treatment for cancer or any other medical condition in the U.S. 714-X is legally available in Canada on compassionate grounds and must be obtained through a physician with permission by government regulatory authorities. Some U.S. citizens have obtained and used this product.

The NCI's BCS Program review of the pertinent medical records, radiographic films and pathology specimens of 17 cancer patients who reportedly received 714-X has been completed. At this time the judgment is that there is insufficient information to justify NCI-initiated research on 714-X as an anticancer therapy. The OCCAM is seeking authorization to solicit referral of other well-documented cases directly from U.S. cancer patients. If approved, such a solicitation will be posted on the OCCAM website (<http://cancer.gov/cam>).